Organization | Irish Group CTI

Irish Group CTI Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2015

NCT02375204

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (8)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

filgrastim (neupogen) (1 trial)

ifosfamide (ifex) (1 trial)

paclitaxel (taxol) (1 trial)

sargramostim (leukine) (1 trial)

stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Choriocarcinoma (Phase 3)

Endodermal Sinus Tumor (Phase 3)

Germinoma (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Seminoma (Phase 3)

Teratoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 8